Exosome-based Nanoplatform for Ldlr mRNA Delivery in FH

Phase 1

Not yet recruiting

• Conditions: Familial Hypercholesterolemia
• Interventions: Biological: Low Density Lipoprotein Receptor mRNA Exosomes

• Registration Number: NCT05043181
• Lead Sponsor: Tang-Du Hospital

Brief Summary

mRNA therapy is a highly promising gene therapeutic strategy in the treatment of Homozygous Familial Hypercholesterolemia (HoFH). Exosomes is safe and efficient carriers for mRNA drug delivery, due to their biocompatibility, bioavailability. This first-in-human study is aimed to evaluate the safety and preliminary effectiveness of Exosome-based ldlr mRNA nanoplatform for gene therapy in HoFH.

Detailed Description

Familial hypercholesterolemia (FH) is an autosomal dominant genetic disease characterized by severely elevated plasma low-density lipoprotein (LDL) cholesterol (LDL-C) and premature coronary heart disease. Most of FH patients (about 95% of cases) are attributed to functional loss mutation of the LDL receptor (LDLR) gene. The prevalence of the heterozygous mutations in LDLR has been estimated at 1 in 200 to 1 in 500 in the population, and the homozygous form in 1 in 100000 individuals. As a key lipoprotein receptor on the surface of hepatocyte, the LDLR is critical for liver clearing LDL-C from the circulation. By endocytosis and further processing of the LDL-C, LDLR is responsible for removing most excess LDL-C from the serum, and there are no substitutes in vivo. These heterozygotes (HeFH) typically have twice the normal plasma LDL levels and cardiovascular diseases at an earlier age. Homozygous individuals (HoFH) face much higher LDL-C levels and often die before the age of 20 years if untreated. Although existing therapeutics, such as statins, ezetimibe and PCSK9 inhibitors, have some beneficial effects on HeFH, few drugs have therapeutic effects on HoFH even at high-doses. Lipid apheresis and liver transplantation are the current clinical managements to reduce the LDL-C level, while gene therapy holds the promise.

Exosomes are small intracellular vesicles ranging in 30-150 nm size and have an important role in cell-cell communication. Many studies show that exosome can efficiently deliver cargos, such as mRNA, miRNA and even plasmid DNA, to target cells, emerging as a promising therapeutic carrier for gene therapy. Compared with virus, exosomes, as "natural nanoparticles", are easy to handle, non-cytotoxic and non-immunogenic. It is thus promising to develop exosome-based LDLR-gene delivery strategy and explore the therapeutic effects on HoFH.

In this study, an Ldlr-expressing virus vector will be constructed to generate Ldlr mRNA-enriched exosomes. To meet the standards of clinical trials, we will use the GMP-grade compliant normal donor bone marrow-derived MSCs to produce exosomes. Exosomes will be enriched by filtration and ultracentrifugation, and then normalized by Nanosight, Electron microscopy and key exosomes biomarkers. In order to ensure the safety of patients, we plan to inject exosomes through abdominal puncture under ultrasound guidance, and purchase medical insurance for patients. This first-in-human study is aimed to evaluate the safety of this exosome product for gene therapy and preliminary evidence of efficacy using plasma LDL-C levels as a surrogate biomarker. The study is promising to provide a new therapeutic approach for the treatment of Homozygous Familial Hypercholesterolemia patients.

Study Timeline

• Status Verified: 2021-09
• Study First Submitted: 2021-09-03
• Study First Submitted QC: 2021-09-03
• Last Update Submitted: 2021-09-03
• Study First Posted: 2021-09-14
• Last Update Posted: 2021-09-14
• Study Start: 2021-12
• Primary Completion: 2026-12
• Study Completion: 2026-12

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Age 18-45, no gender limitation;
2. Patients with homozygous familial hypercholesterolemia diagnosed by genetic testing.
3. Understand the study and be willing to participate in the study with the informed consent signed

Exclusion Criteria

1. those who have severe comorbidities, including any of the following: A) unstable angina pectoris and/or congestive heart failure requiring hospitalization; B) myocardial infarction or cerebrovascular accident within the last 6 months; C) chronic obstructive pulmonary disease worsens or requires hospitalization; D) serious diseases of vascular, nervous system, blood, gastrointestinal and endocrine systems or metabolic disorders; E) autoimmune/immune deficiency diseases such as rheumatoid arthritis, acquired immune deficiency syndrome, and so on; F) malignant tumor or other chronic infection.
2. those who previously received targeted drug therapy, cell therapy, gene therapy or others immunotherapy;
3. those who had organ transplants in the past;
4. any of the following abnormalities are found in the laboratory examination: A) blood routine examination: absolute neutrophil count (ANC) < 1.5×109/L, or platelet (PLT) < 50×109/L, or hemoglobin (HGB) < 80 g/dL; B) coagulation function: prothrombin time (PT), or activated partial thrombin time (APTT), or INR > 1.5×ULN; C) liver function: total bilirubin (TBIL) > 2×ULN (upper limit of normal value), or alanine transferase (ALT), aspartate transferase (AST), alkaline phosphatase (ALP) > 5×ULN; D) renal function: serum creatinine (Cr) ≥1.5×ULN, or glomerular filtration rate (GFR) < 60 mL/min·1.73m2; E) cardiac ultrasound: left ventricular ejection fraction (LVEF) < 50%.
5. those who are known or expected to have an allergic reaction to or have a history of allergic reaction to any of the ingredients treated by this test;
6. those who have a history of contrast agent allergic;
7. those who have a clear history of mental disorders in the past;
8. those who have a history of drug abuse or drug use;
9. Pregnant or lactating women;
10. Women of childbearing age and fertile men cannot take effective and adequate contraceptive measures (such as intrauterine device (IUD), condom, spermicidal gel plus condom, uterine cap, etc.) during the period of receiving the study drug and 3 months after the end of the study;
11. those who participated in the clinical study of other drugs within 3 months before joining the group;
12. Subjects that are not suitable to participate in this study for other reasons judged by the investigators.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Homozygous Familial Hypercholesterolemia	Low Density Lipoprotein Receptor mRNA Exosomes	-

Primary Outcome Measures

Name	Time	Method
Changes of Total Cholesterol	Changes from Baseline Total Cholesterol at Day 19	mmol/L
Changes of Low-Density Lipoprotein Cholesterol	Changes from Baseline Low-Density Lipoprotein Cholesterol at Day 19	mmol/L
Changes of High-Density Lipoprotein Cholesterol	Changes from Baseline High-Density Lipoprotein Cholesterol at Day 19	mmol/L
Changes of Triglyceride	Changes from Baseline Triglyceride at Day 19	mmol/L

Secondary Outcome Measures

Name	Time	Method
Changes of Stability of Carotid Artery Plaques	Changes from Baseline Stability of Carotid Artery Plaques at Day 28	Grade I, II, III determined by ultrasound
Changes of Degree of Coronary Stenosis	Changes from Baseline Degree of Coronary Stenosis at Day 28	% determined by coronary CT
Changes of Volume of Carotid Artery Plaques	Changes from Baseline Volume of Carotid Artery Plaques at Day 28	cm3 determined by ultrasound

Trial Locations

Locations (1)

Tangdu Hospital, Air Force Medical University; 🇨🇳 Xi'an, Shannxi, China